OncoMatch/Clinical Trials/NCT06519526
Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Is NCT06519526 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SHR-0302 and SHR-2554 for relapsed/refractory peripheral t cell lymphoma.
Treatment: SHR-0302 · SHR-2554 — This is an open-label, prospective and exploratory clinical study to evaluate the efficacy and safety of JAK inhibitor SHR-0302 in combination with EZH2 inhibitor SHR-2554 in patients with R/R PTCL. The study plans to enroll approximately 25 patients. 6-12 patients will receive SHR-0302 monotherapy and SHR-0302+SHR-2554 combination therapy in the safety run-in phase. According to the safety observed, the investigators discuss and decide to select a dose group to explore the efficacy and safety. 13 patients may be enrolled in the expansion phase.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor treatment
Received anti-tumor treatment within 28 days prior to the first dose of the study drug
Cannot have received: Chinese medicine treatment with anti-tumor effect
received Chinese medicine treatment with anti-tumor effect within 14 days before the first dose of the study drug
Cannot have received: steroid hormones
received steroid hormones within 7 days prior to the first dose of study drug administration
Lab requirements
Blood counts
adequate bone marrow reserve
Kidney function
adequate organ system function reserve
Liver function
adequate organ system function reserve
Adequate bone marrow reserve and organ system function reserve
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify